Jennison Associates
ARCT icon

Jennison Associates’s Arcturus Therapeutics ARCT Stock Holding History

Jennison Associates’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-22,143
Closed -$961K – 666
2020
Q4 		$961K Sell
22,143
-973
-4% -$65.9K ﹤0.01% 586
2020
Q3 		$992K Sell
23,116
-138,308
-86% -$6.87M ﹤0.01% 549
2020
Q2 		$7.54M Buy
+161,424
New +$5.56M 0.01% 402

Other funds holding ARCT

ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates's ARCT Position: Q1 2021 in Review

Jennison Associates sold out of Arcturus Therapeutics (ARCT) in Q1 2021, closing a stake of 22,143 shares — an estimated $961K sold.

Jennison Associates first reported a position in ARCT in Q2 2020 and held it in 3 quarters. The position peaked at $7.54M in Q2 2020. 162 funds tracked by Wall St. Rank hold ARCT as of Q1 2021.

  • Jennison Associates reported no remaining Arcturus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Jennison Associates sold 22,143 Arcturus Therapeutics shares in Q1 2021, an estimated $961K.
  • Jennison Associates first reported a position in Arcturus Therapeutics in Q2 2020 and held it in 3 quarters.
  • Jennison Associates's Arcturus Therapeutics position peaked at $7.54M in Q2 2020.
  • 162 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2021.

Based on Jennison Associates's 13F filing for Q1 2021, filed 11 May 2021.